Pharmafile Logo

quantum physics

- PMLiVE

Moderna to launch Innovation and Technology Center in the UK

With support from the UK government, the manufacturing facility is expected to produce up to 250 million doses annually

- PMLiVE

Moderna announces trial results for new COVID-19 booster vaccine candidate

The new vaccine candidate offers nearly twice as much protection against Omicron as Spikevax

- PMLiVE

Moderna wins Prix Galien UK Award for best biotechnology product

The Prix Galien Awards ceremony was held at the National History Museum in London

AI in Healthcare: How to Accelerate Change

Harry Glorikian, Author & General Partner at Scientia Ventures, dives into the current and future applications of AI and other innovative health technologies, including for personalized medicine, drug development, public...

Impetus Digital

- PMLiVE

Moderna appoints Jorge Gomez as chief financial officer

Gomez’s new role will begin on 9 May 2022

- PMLiVE

Moderna applies to FDA for authorisation for second COVID-19 booster shot for all adults

The second booster shot would be for adults 18 years and over who have already had one authorised COVID-19 booster shot

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Research Partnership

- PMLiVE

Moderna begins phase 2 trial of Omicron-specific booster

The study will include two groups, with approximately 300 people in each group

GHO Logo

GHO Capital Acquires Genesis Research

GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes...

Genesis Research Group

EVID AI literature review platform

Genesis Research: What is EVID AI?

Genesis Research Announces Significant Enhancements to EVID AI, the World's Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches

Genesis Research Group

- PMLiVE

US FDA expands COVID-19 booster jabs to all adults

All Americans 18 and over are now eligible to receive a booster shot of either the Pfizer/BioNTech or Moderna COVID-19 vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links